Revvity, Inc cash flow statement RVTY

In fiscal 2025, which ended Dec 28, 2025, Revvity, Inc generated $582.9 million of cash from operations, down 7.2% from the year before. It spent $73.5 million on capital expenditures. That left free cash flow of $509.4 million. The company returned $32.8 million in dividends and $820.8 million in share buybacks to shareholders.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line
FY 2026
Jul 5, 2026
FY 2025
Dec 28, 2025
FY 2024
Dec 29, 2024
FY 2023
Dec 31, 2023
FY 2022
Jan 1, 2023
FY 2021
Jan 2, 2022
FY 2020
Jan 3, 2021
FY 2019
Dec 29, 2019
FY 2018
Dec 30, 2018
FY 2017
Dec 31, 2017
FY 2016
Jan 1, 2017
Operating
Depreciation and amortization
412
-0.2%
405
-5.3%
428
-0.9%
432
+1.1%
427
+37.1%
311
+54.4%
202
-5.8%
214
+18.5%
181
+72.0%
105
+5.0%
100
-5.1%
Stock-based compensation
24
-27.0%
23
-39.6%
38
-8.7%
41
-19.6%
52
+73.6%
30
+10.3%
27
-14.6%
32
+9.5%
29
+13.2%
25
+48.2%
17
-0.7%
Operating cash flow
628
+7.4%
583
-7.2%
628
+588.4%
91
-86.6%
680
-51.8%
1,411
+58.1%
892
+145.5%
363
+16.9%
311
+7.8%
288
-17.7%
351
+22.1%
Investing
Capital expenditures
70
-14.8%
74
-15.1%
87
+6.5%
81
-5.0%
86
-0.5%
86
+35.2%
64
-16.6%
76
-18.1%
93
+138.6%
39
+23.3%
32
+12.3%
Investing cash flow
-83
-112.7%
-17
-102.2%
776
-40.9%
1,314
+1088.7%
-133
+96.8%
-4,113
-715.2%
-504
-3.5%
-488
-205.0%
-160
+87.4%
-1,267
-1409.9%
-84
+16.8%
Financing
Dividends paid
32
-6.3%
33
-4.8%
34
-1.5%
35
-1.1%
35
+9.2%
32
+3.7%
31
+0.5%
31
+0.2%
31
+0.7%
31
-0.0%
31
-2.4%
Stock buybacks
476
-39.5%
821
+122.1%
370
-5.0%
389
+382.3%
81
+10.4%
73
+952.3%
7
+10.0%
6
-89.0%
57
+1398.3%
4
-97.5%
152
+98.6%
Financing cash flow
-503
+67.2%
-858
+24.0%
-1,128
-19.1%
-947
-43.1%
-662
-122.5%
2,942
+1550.0%
-203
-35.1%
-150
+16.2%
-179
-122.9%
782
+780.1%
-115
-7.3%
Change in cash
Effect of exchange rate
-10
-128.0%
49
+285.6%
-26
-86.1%
-14
+58.4%
-34
-47.2%
-23
-188.5%
26
+5897.1%
-0
+94.4%
-8
—
—
Net change in cash
31
+112.2%
-243
-197.3%
250
-43.6%
444
+398.6%
-149
-168.6%
217
+2.8%
211
+723.8%
26
+170.9%
-36
—
—
Free cash flow
558
+11.0%
509
-6.0%
542
+5369.0%
10
-98.3%
594
-55.1%
1,325
+59.9%
829
+188.6%
287
+31.8%
218
-12.7%
249
-21.8%
319
+23.2%
Per share
Free cash flow per share
4.94
+18.3%
4.37
-0.9%
4.41
+5457.6%
0.08
-98.3%
4.70
-58.6%
11.35
+53.6%
7.39
+187.0%
2.58
+31.9%
1.95
-13.2%
2.25
-22.2%
2.89
+26.5%
Dividend per share
—
0.28
+0.0%
0.28
+0.0%
0.28
—
—
0.28
+0.0%
0.28
+0.0%
0.28
+0.0%
0.28
+0.0%
0.28
+0.0%
Shareholder returns
Returned to shareholders
508
854
404
424
116
105
38
37
88
35
183
Share of free cash flow
90.94%
167.57%
74.59%
4,279.56%
19.52%
7.96%
4.61%
13.02%
40.62%
13.89%
57.26%
Ratios
Free cash flow margin
19.17%
17.84%
19.66%
0.36%
17.94%
34.61%
31.11%
9.96%
7.84%
11.05%
15.07%
Capital expenditures to revenue
2.39%
2.57%
3.15%
2.96%
2.59%
2.25%
2.39%
2.65%
3.36%
1.73%
1.50%
Stock-based compensation to revenue
0.84%
0.80%
1.37%
1.51%
1.56%
0.78%
1.01%
1.09%
1.04%
1.13%
0.81%
Cash conversion
2.64x
2.42x
2.32x
0.13x
1.19x
1.50x
1.23x
1.60x
1.31x
0.99x
1.50x
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Laboratory Analytical Instruments (SIC 3826)
Listed as
RVTY (NYSE)
Fiscal year ends
December 29
Incorporated in
MA
Headquarters
Waltham, MA
SEC filer status
Large accelerated filer
SEC CIK
31791
Former names
PERKINELMER INC (until Apr 14, 2023); EG&G INC (until Jul 26, 1999)

Other Laboratory Analytical Instruments companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.